Millipore Sigma Vibrant Logo

476275 Myricetin - CAS 529-44-2 - Calbiochem

View Products on Sigmaaldrich.com
476275
Visualizza prezzi e disponibilità

Panoramica

Replacement Information

Tabella delle specifiche principali

CAS #Empirical Formula
529-44-2C₁₅H₁₀O₈

Prezzi e disponibilità

Numero di catalogo DisponibilitàConfezionamento Qtà/conf Prezzo Quantità
476275-25MG
Verifica della disponibilità in corso...
Disponibilità limitata
Disponibilità limitata
A magazzino 
Fuori produzione
Disponibili quantità limitate
La disponibilità deve essere confermata
    Prodotti rimanenti: riceverà un nostro avviso
      Prodotti rimanenti: riceverà un nostro avviso
      Will advise
      Contatti il Servizio Clienti
      Contact Customer Service

      Fiala di plastica 25 mg
      Ricerca del prezzo in corso...
      Non è stato possibile trovare il prezzo
      La quantità minima deve essere un multiplo di
      Maximum Quantity is
      Al termine dell'ordine Maggiori informazioni
      Lei ha salvato ()
       
      Richiedi il prezzo
      Description
      OverviewA cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties. Acts as a non-ATP competitive MEK1 inhibitor (IC50 < 3 µM), and ATP-competitive inhibitors of CKI, CKII, IR, MLCK, PKA and PKC (Ki = 9.0 µM, 0.6 µM, 2.6 µM, 1.7 µM, 27.5 µM and 12.1 µM, respectively) and PI 3-Kα and PIM-1 (IC50 = 1.8 µM and 0.78 µM). Reported to inhibit the activities of phosphodiesterase 1-4 (IC50 < 40 µM) and MMP-2 (IC50 < 24 µM in several colorectal carcinoma cells), and block TNFα-mediated NF-κB signaling (at 50 µM in ECV304 cells) and insulin-stimulated glucose transport (Ki = ~ 33.5 µM in rat adipocytes). Further, induce apoptosis in HL-60 leukemia cells with an IC50 of 43 µM.
      Catalogue Number476275
      Brand Family Calbiochem®
      Synonyms3,3ʹ,4ʹ,5,5ʹ,7-Hexahydroxyflavone, Hsp70 Inhibitor II
      References
      ReferencesLee, K.W., et al. 2007. Carcinogenesis 28, 1918.
      Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
      Strobel, P., et al. 2005. Biochem. J. 386, 471.
      Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
      Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
      Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
      Walker, E.H., et al. 2000. Mol. Cell 6, 909.
      Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
      Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.
      Product Information
      CAS number529-44-2
      FormYellowish brown solid
      Hill FormulaC₁₅H₁₀O₈
      Chemical formulaC₁₅H₁₀O₈
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Numero di catalogo GTIN
      476275-25MG 04055977184471

      Documentation

      Myricetin - CAS 529-44-2 - Calbiochem MSDS

      Titolo

      Scheda di sicurezza (MSDS) 

      Myricetin - CAS 529-44-2 - Calbiochem Certificati d'Analisi

      TitoloNumero di lotto
      476275

      Riferimenti bibliografici

      Panoramica delle referenze
      Lee, K.W., et al. 2007. Carcinogenesis 28, 1918.
      Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
      Strobel, P., et al. 2005. Biochem. J. 386, 471.
      Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
      Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
      Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
      Walker, E.H., et al. 2000. Mol. Cell 6, 909.
      Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
      Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.
      Scheda tecnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision21-November-2008 JSW
      Synonyms3,3ʹ,4ʹ,5,5ʹ,7-Hexahydroxyflavone, Hsp70 Inhibitor II
      DescriptionA cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties. Acts as a non-ATP competitive MEK1 inhibitor (IC50 < 3 µM), and ATP-competitive inhibitors of CKI, CKII, IR, MLCK, PKA and PKC (Ki = 9.0 µM, 0.6 µM, 2.6 µM, 1.7 µM, 27.5 µM and 12.1 µM, respectively) and PI 3-Kα and PIM-1 (IC50 = 1.8 µM and 0.78 µM). Reported to inhibit the activities of phosphodiesterase 1-4 (IC50 < 40 µM) and MMP-2 (IC50 < 24 µM in several colorectal carcinoma cells), and block TNFα-mediated NF-κB signaling (at 50 µM in ECV304 cells) and insulin-stimulated glucose transport (Ki ~ 33.5 µM in rat adipocytes). Further, induce apoptosis in HL-60 leukemia cells with an IC50 of 43 µM.
      FormYellowish brown solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number529-44-2
      Chemical formulaC₁₅H₁₀O₈
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (5 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesLee, K.W., et al. 2007. Carcinogenesis 28, 1918.
      Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
      Strobel, P., et al. 2005. Biochem. J. 386, 471.
      Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
      Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
      Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
      Walker, E.H., et al. 2000. Mol. Cell 6, 909.
      Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
      Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.